MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.

PloS One 2019 November 25 [Link] Minchom A, Mak D, Gunapala R, Walder D, Kumar R, Yousaf N, Hodgkiss A, Bhosle J, Popat S, O’Brien MER Abstract OBJECTIVES: Vitamin supplementation reduces pemetrexed toxicity. Raised plasma homocysteine reflects deficiency in vitamin B12 and folate, and is suppressed by supplementation. This observational study of 112 patients receiving […]

December 5, 2019

Full Archive, Lung Cancer, Pemetrexed (Alimta), Pleural
Comments Off on A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.

Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

Clinical Lung Cancer 2019 October 25 [Link] Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M Abstract BACKGROUND: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed […]

November 28, 2019

Biomarkers, Chemotherapy, Cisplatin (Platinol ®), CT or CAT scan, Full Archive, Lung Cancer, Pleural
Comments Off on Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype.

Molecular Cancer Research 2019 Novemver 15 [Link] Eckert RL, Kandasamy S, Adhikary G, Rorke EA, Friedberg JS, Mickle MB, Alexander HR Abstract Mesothelioma is an aggressive cancer that has a poor prognosis. Tumors develop in the mesothelial lining of the pleural and peritoneal cavities in response to asbestos exposure. Surgical debulking followed by chemotherapy is […]

November 27, 2019

Chemotherapy, Epithelioid, Full Archive, Peritoneal (Abdominal Mesothelioma), Pleural, Sarcomatoid
Comments Off on The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype.

The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.

Anticancer Research 2019 November [Link] Kuroda A, Matsumoto S, Fukuda A, Nakamichi T, Nakamura A, Hashimoto M, Takuwa T, Kondo N, Tsujimura T, Nakano T, Hasegawa S Abstract BACKGROUND/AIM: We performed multimodality therapy comprising preoperative chemotherapy, extrapleural pneumonectomy (EPP), and radiation therapy for patients with malignant pleural mesothelioma (MPM). Although multimodality therapy resulted in good […]

November 19, 2019

Chemotherapy, Extrapleural Pneumonectomy (EPP), Full Archive, Immunohistochemistry or IHC, Pleural, Radiation
Comments Off on The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.

CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.

Molecular Cancer Therapeutics 2019 November 6 [Link] Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, Schmid RA, Peng RW Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with dismal prognosis, largely due to poor response rates to and rapid relapse after first-line […]

November 18, 2019

Chemotherapy, Cisplatin (Platinol ®), Full Archive, Pemetrexed (Alimta), Pleural
Comments Off on CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.

Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.

Frontiers in Oncology 2019 October 11 [Link] Abstract Introduction: Globular C1q receptor (gC1qR/p32/HABP1) is overexpressed in a variety of cancers, particularly adenocarcinomas. This study investigated gC1qR expression in malignant pleural mesothelioma (MPM) and its pathophysiologic correlates in a surgical patient cohort. Methods: Tissue microarrays comprising 6 tumoral and 3 stromal cores from 265 patients with MPM (216 epithelioid, […]

November 15, 2019

Biphasic or Mixed, Chemotherapy, Epithelioid, Full Archive, Immunohistochemistry or IHC, Pleural, Sarcomatoid, Surgery
Comments Off on Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.

Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin.

International Journal of Molecular Science 2019 October 29 [Link] Wörthmüller J, Salicio V, Oberson A, Blum W, Schwaller B Abstract Malignant mesothelioma (MM) is an aggressive asbestos-linked neoplasm, characterized by dysregulation of signaling pathways. Due to intrinsic or acquired chemoresistance, MM treatment options remain limited. Calretinin is a Ca2+-binding protein expressed during MM tumorigenesis that […]

November 12, 2019

Causation, Cisplatin (Platinol ®), Full Archive
Comments Off on Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin.

Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Frontiers in Cell and Developmental Biology 2019 October 1 [Link] Johnson TG, Schelch K, Mehta S, Burgess A, Reid G Abstract Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have […]

October 31, 2019

Biomarkers, Chemotherapy, Full Archive, Lung Cancer, Pleural
Comments Off on Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2).

Trials 2019 October 18 [Link] Warnock C, Lord K, Taylor B, Tod A Abstract BACKGROUND: The Mesothelioma and Radical Surgery Trial (MARS 2) aims to evaluate a surgical procedure by comparing chemotherapy and surgery against chemotherapy alone. The pilot study for MARS 2 evaluated the viability of recruitment. Challenges have been reported in conducting clinical […]

October 29, 2019

Chemotherapy, Full Archive, Pleural, Surgery
Comments Off on Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2).

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

Lancet Oncology 2019 October 15 [Link] Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F Abstract BACKGROUND: Tumour Treating Fields (TTFields) are a regional, antimitotic treatment for solid tumours, which is based on […]

October 28, 2019

Chemotherapy, Cisplatin (Platinol ®), Full Archive, Pleural
Comments Off on Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.